EATG » Portfolios

HIV/TB portfolio

Tuberculosis (TB) is one of the leading causes of death for people living with HIV globally. The EATG operates a portfolio to explore and discuss issues around HIV and TB…

Viral Hepatitis Portfolio

Viral hepatitis (HCV and HBV) remain one of the most important killers of people living with HIV. The EATG has been working in the field of community education and mobilisation,…

HIV Cure Portfolio

In recent years, there has been a renewed scientific focus on curing HIV infection followed by strong interest on the side of community and HIV treatment organizations to support these…

Training and Capacity Building – TCWG

The Training and Capacity Building Working Group - Training, capacity building and the group of trainers Capacity building is a continuous process at EATG. An important part of our work…

HIV/TB portfolio

Tuberculosis (TB) is one of the leading causes of death for people living with HIV globally. The EATG operates a portfolio to explore and discuss issues around HIV and TB…

Viral Hepatitis Portfolio

Viral hepatitis (HCV and HBV) remain one of the most important killers of people living with HIV. The EATG has been working in the field of community education and mobilisation,…

Prevention of HIV infection – PrEP, vaccines, microbicides etc.

The EATG has been engaged in HIV prevention since the earliest years of "Positive Prevention". Partnering primarily with AVAC, we have been operating an extensive and scientifically grounded prevention portfolio…

Access to and affordability of medicines and diagnostics

Recognising that the access to and affordability of medicines is one of the biggest challenges for people living with HIV in WHO Europe, the EAG operates a comprehensive portfolio on…

Policy – The Policy Working Group – PWG

Improving HIV/AIDS Policy at European and International level EATG’s policy activities focus on treatment advocacy and in particular on equal access to early diagnosis, adequate treatment for HIV and co-infections.…

HIV/TB portfolio

Tuberculosis (TB) is one of the leading causes of death for people living with HIV globally. The EATG operates a portfolio to explore and discuss issues around HIV and TB…

Viral Hepatitis Portfolio

Viral hepatitis (HCV and HBV) remain one of the most important killers of people living with HIV. The EATG has been working in the field of community education and mobilisation,…

HIV Cure Portfolio

In recent years, there has been a renewed scientific focus on curing HIV infection followed by strong interest on the side of community and HIV treatment organizations to support these…

Prevention of HIV infection – PrEP, vaccines, microbicides etc.

The EATG has been engaged in HIV prevention since the earliest years of "Positive Prevention". Partnering primarily with AVAC, we have been operating an extensive and scientifically grounded prevention portfolio…

Access to and affordability of medicines and diagnostics

Recognising that the access to and affordability of medicines is one of the biggest challenges for people living with HIV in WHO Europe, the EAG operates a comprehensive portfolio on…

Science – European Community Advisory Board – ECAB

The European Community Advisory Board - ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies,…